<DOC>
	<DOCNO>NCT02399085</DOCNO>
	<brief_summary>This open-label , multicentre study characterize safety efficacy human anti CD19 antibody MOR00208 combination Lenalidomide adult subject relapsed/refractory Diffuse Large B-cell Lymphoma ( DLBCL ) least one , three prior systemic regimen eligible high dose chemotherapy ( HDC ) autologous stem-cell transplantation ( ASCT ) time study entry .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Lenalidomide With MOR00208 Patients With R-R DLBCL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Major 1 . Age &gt; 18 year 2 . Histologically confirm diagnosis DLBCL 3 . Tumour tissue central pathology review correlative study must provide . 4 . Patients must : relapse and/or refractory disease least one bidimensionally measurable , PET positive disease site ( transverse diameter ≥1.5 cm perpendicular diameter ≥1.0 cm baseline ) receive least one , three previous systemic regimen treatment DLBCL one therapy line must include CD20targeted therapy Eastern Cooperative Oncology Group 0 2 5 . Patients consider opinion investigator eligible , patient unwilling undergo intensive salvage therapy include ASCT 6 . Patients must meet follow laboratory criterion screen : absolute neutrophil count ≥1.5 × 109/L platelet count ≥90 × 109/L total serum bilirubin ≤2.5 × ULN ≤5 × ULN case Glibert 's Syndrome liver involvement lymphoma alanine transaminase , aspartate aminotransferase alkaline phosphatase ≤3 × ULN &lt; 5 × ULN case liver involvement serum creatinine clearance ≥60 mL/minute 7 . Females childbearing potential ( FCBP ) must : pregnant refrain breastfeed donate blood oocyte agree ongoing pregnancy test commit continue abstinence heterosexual intercourse , agree use able comply use doublebarrier contraception 8 . Males ( sexually active FCBP ) must use effective barrier method contraception refrain donate blood sperm 9 . In opinion investigator patient must : able willing receive adequate prophylaxis and/or therapy thromboembolic event able understand reason comply special condition pregnancy prevention risk management plan give write acknowledgement . Major 1 . Patients : histological type lymphoma primary refractory DLBCL history `` double/triple hit '' genetics 2 . Patients , within 14 day prior Day 1 dosing : discontinue CD20targeted therapy , chemotherapy , radiotherapy , investigational anticancer therapy lymphoma specific therapy undergone major surgery suffer significant traumatic injury receive live vaccine . require parenteral antimicrobial therapy active , intercurrent infection 3 . Patients : previously treat CD19targeted therapy IMiDs® ( e.g . thalidomide , LEN ) undergone ASCT within period ≤ 3 month prior sign inform consent form . undergone previous allogenic stem cell transplantation history deep venous thrombosis/embolism willing/able take venous thromboembolic event prophylaxis entire treatment period concurrently use anticancer experimental treatment 4 . Prior history malignancy DLBCL , unless patient free disease ≥5 year prior screen . 5 . Patients : positive hepatitis B and/or C serology . know seropositivity history active viral infection human immunodeficiency virus ( HIV ) CNS lymphoma involvement history evidence clinically significant cardiovascular , CNS and/or systemic disease would investigator 's opinion preclude participation study compromise patient 's ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>CD19</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>MOR00208</keyword>
	<keyword>MOR208</keyword>
</DOC>